Fundamental Analysis Stories

EQBK
  over six months ago at Macroaxis 
By Raphi Shpitalnik
Equity Bancshares Asset Turnover is decreasing as compared to previous years. The last year's value of Asset Turnover was reported at 0.0297. The current Debt to Equity Ratio is estimated to increase to 6.78, while Average Assets are projected to decrease to under 4 B. One of the important factors of profitable assets selection is to know the future growth potential of an asset before buying its shares. This post will examine Equity Bancshares. We will evaluate why we are still confident in anticipation of a recovery. Equity Bancshares almost neglects market trends. We can now concentrate on Equity as a potential investment option for your portfolios.
BXS
  over six months ago at Macroaxis 
By Achuva Shats
BancorpSouth Bank Enterprise Value over EBITDA is relatively stable at the moment as compared to the past year. BancorpSouth Bank reported last year Enterprise Value over EBITDA of 14.51. As of 01/25/2021, Free Cash Flow per Share is likely to grow to 1.37, while Revenue Per Employee is likely to drop slightly above 188.5 K. If you have been following BancorpSouth you may be considering buying. Let's check if invariable basic indicators will continue to push the price to spike for BancorpSouth Bank's retail investors. The entity barely shadows the market. We can now discuss BancorpSouth as a potential investment option for your portfolios.
PRK
  over six months ago at Macroaxis 
By Raphi Shpitalnik
Park National Cash Flow Per Share is decreasing as compared to previous years. The last year's value of Cash Flow Per Share was reported at 7.81. The current Revenue to Assets is estimated to increase to 0.06, while Average Assets are projected to decrease to under 6.1 B. Park National is scheduled to announce its earnings tomorrow. The upcoming quarterly report is expected on the 26th of January 2021. Is financial services space attracting new traders, let's check if Park National is sending any bullish signals. We will analyze why Park National investors may still consider a stake in the business. The entity moves indifferently to market moves. We can now concentrate on Park National as a potential investment option for your portfolios.
NNDM
  over six months ago at Macroaxis 
By Achuva Shats
Even with relatively sluggish basic indicators, Nano Dimension revealed solid returns over the last few months and may actually be approaching a breakup point. We currently estimate Nano Dimension as overvalued. The real value is approaching 10.06 per share.
CLPT
  over six months ago at Macroaxis 
By Raphi Shpitalnik
In spite of comparatively unfluctuating basic indicators, Clearpoint Neuro unveiled solid returns over the last few months and may actually be approaching a breakup point. We currently estimate Clearpoint Neuro as overvalued. The real value is approaching 18.26 per share.
NTN
  over six months ago at Macroaxis 
By Gabriel Shpitalnik
NTN Buzztime Market Capitalization is quite stable at the moment as compared to the past year. The company's current value of Market Capitalization is estimated at 5.89 Million. Tangible Asset Value is expected to rise to about 14.2 M this year, although the value of Earnings before Tax will most likely fall to (2 M). The stock is still going through an active upward rally. Is communication services space attracting new institutional investors, let's check if NTN Buzztime is sending any bullish signals. I will address the reasons this entity was abused by institutional investors resulted from the current market uncertainty. The entity barely shadows the market. We can now inspect NTN Buzztime as a potential investment option for your portfolios.
GRAY
  over six months ago at Macroaxis 
By Achuva Shats
In spite of fairly fragile fundamental drivers, Graybug Vision may actually be approaching a critical reversion point that can send shares even higher in February 2021. Will investors continue to hold, or should we expect a sell-off?
SLB
  over six months ago at Macroaxis 
By Achuva Shats
If you have been following Schlumberger you may be considering taking in. Let's check if strong basic indicators will continue to push the price to rise for Schlumberger's investors. Will investors continue to hold, or should we expect a sell-off?
ORMP
  over six months ago at Macroaxis 
By Achuva Shats
In spite of very unsteady technical and fundamental indicators, Oramed Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in February 2021. Will insiders continue to hold, or should we expect a sell-off?
BVXV
  over six months ago at Macroaxis 
By Achuva Shats
In spite of fairly weak fundamental indicators, BiondVax Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in February 2021. Will sophisticated investors continue to hold, or should we expect a sell-off?